The company said on January 5, 2024 that it had appointed Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment, effective January 8, 2024.

1. 01

   The company said on January 5, 2024 that it had appointed Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment, effective January 8, 2024.

2. 02

   The company said its executive employment agreement with McManus, entered into on January 4, 2024, has an initial term of 3 years commencing on January 8, 2024, with an annual base salary of $550,000 and an annual cash incentive target of 90% of base salary.

3. 03

   The company said it will grant McManus a one-time restricted stock unit award with a grant date value of $950,000, vesting in equal installments over 3 years. It said the annual equity package, prorated for the number of months McManus is employed during FY2024, includes time-vested options worth approximately $950,000, a performance-vested option worth approximately $475,000, and performance-based restricted stock units worth $475,000.

4. 04

   The company said that if McManus is terminated without Cause by the company, terminated by the company following a Change in Control, or resigns for Good Reason, he will receive severance equal to 1 year of his current base salary, a prorated portion of his annual cash incentive, and health insurance coverage for 1 year, paid in exchange for his release of claims.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.